John C. Byrd
Impact in
- Hematology top 0.5%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
Papers in
- Genetics 53
- Chronic Lymphocytic Leukemia Research 48
- Hematology 29
- Acute Myeloid Leukemia Research 19
- Chronic Myeloid Leukemia Treatments 12
- Co-authors
- Gerard Lozanski (8 shared papers)Kristie A. Blum (3 shared papers)Guido Marcucci (8 shared papers)Michael R. Grever (19 shared papers)David Lucas (4 shared papers)Shinichi Kitada (2 shared papers)Melanie E. Davis (2 shared papers)Mark R. Parthun (2 shared papers)
- Journals
- Blood (27 papers)Journal of Clinical Oncology (7 papers)HemaSphere (5 papers)Leukemia (5 papers)Blood Advances (4 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
John C. Byrd
75 papers receiving 3.6k citations
John C. Byrd's Hit Papers
Peers
Comparison fields: 5 of 93
- Hematology 1.5k
- Genetics 1.2k
- Pathology and Forensic Medicine 884
- Oncology 618
- Immunology 462
Countries citing papers authored by John C. Byrd
This map shows the geographic impact of John C. Byrd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Byrd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Byrd more than expected).
Fields of papers citing papers by John C. Byrd
This network shows the impact of papers produced by John C. Byrd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Byrd. The network helps show where John C. Byrd may publish in the future.
Co-authors
The 25 scholars most cited alongside John C. Byrd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 82 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Hit paper breakdown → | 2002 | 1185 |
| 2 | 2002 | 447 | |
| 3 | 2004 | 367 | |
| 4 | 2004 | 322 | |
| 5 | 2007 | 271 | |
| 6 | 2003 | 142 | |
| 7 | 2004 | 116 | |
| 8 | 1995 | 89 | |
| 9 | 2023 | 70 | |
| 10 | 2004 | 62 | |
| 11 | 2015 | 61 | |
| 12 | 2008 | 54 | |
| 13 | 1996 | 42 | |
| 14 | 2023 | 33 | |
| 15 | 2022 | 32 | |
| 16 | 2008 | 28 | |
| 17 | 2012 | 24 | |
| 18 | 2001 | 22 | |
| 19 | 2021 | 19 | |
| 20 | 2011 | 18 |
About John C. Byrd
John C. Byrd is a scholar working on Genetics, Hematology, Molecular Biology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 82 papers that have together received 3.7k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (48 papers), Acute Myeloid Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (17 papers), Chronic Myeloid Leukemia Treatments (12 papers), Advanced Breast Cancer Therapies (9 papers), Acute Lymphoblastic Leukemia research (9 papers), Immunodeficiency and Autoimmune Disorders (7 papers) and Protein Degradation and Inhibitors (5 papers). The work is most often cited by research in Hematology (1.5k citations), Genetics (1.2k citations), Pathology and Forensic Medicine (884 citations), Oncology (618 citations) and Immunology (462 citations). John C. Byrd has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Gerard Lozanski, Kristie A. Blum, Guido Marcucci, Michael R. Grever, David Lucas, Shinichi Kitada, Melanie E. Davis, Mark R. Parthun, John C. Reed and Joseph Wickham. Their work appears in journals such as Blood, Journal of Clinical Oncology, HemaSphere, Leukemia and Blood Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.